Latest & greatest articles for amiodarone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on amiodarone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on amiodarone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for amiodarone

41. Amiodarone versus implantable defibrillator (AMIOVIRT): background, rationale, design, methods, results and implications

Amiodarone versus implantable defibrillator (AMIOVIRT): background, rationale, design, methods, results and implications Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2003 NHS Economic Evaluation Database.

42. Low-dose oral amiodarone prophylaxis reduces atrial fibrillation after pulmonary resection

Low-dose oral amiodarone prophylaxis reduces atrial fibrillation after pulmonary resection Low-dose oral amiodarone prophylaxis reduces atrial fibrillation after pulmonary resection Low-dose oral amiodarone prophylaxis reduces atrial fibrillation after pulmonary resection Lanza L A, Visbal A I, DeValeria P A, Zinsmeister A R, Diehl N N, Trastek V F Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief (...) summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of low-dose oral amiodarone (LDOA) as prophylactic treatment for atrial fibrillation (AF) after pulmonary resection. LDOA comprised 200 mg by mouth every 8 hours. Treatment was started after recovery from general anaesthesia and was discontinued at dismissal. Type of intervention Secondary prevention. Economic study type

2003 NHS Economic Evaluation Database.

43. Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. (Abstract)

Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. Lidocaine has been the initial antiarrhythmic drug treatment recommended for patients with ventricular fibrillation that is resistant to conversion by defibrillator shocks. We performed a randomized trial comparing intravenous lidocaine with intravenous amiodarone as an adjunct to defibrillation in victims of out-of-hospital cardiac arrest.Patients were enrolled if they had out-of-hospital ventricular (...) fibrillation resistant to three shocks, intravenous epinephrine, and a further shock; or if they had recurrent ventricular fibrillation after initially successful defibrillation. They were randomly assigned in a double-blind manner to receive intravenous amiodarone plus lidocaine placebo or intravenous lidocaine plus amiodarone placebo. The primary end point was the proportion of patients who survived to be admitted to the hospital.In total, 347 patients (mean [+/-SD] age, 67+/-14 years) were enrolled

2002 NEJM Controlled trial quality: predicted high

44. An economic analysis of amiodarone versus placebo for the prevention of atrial fibrillation after open heart surgery

An economic analysis of amiodarone versus placebo for the prevention of atrial fibrillation after open heart surgery An economic analysis of amiodarone versus placebo for the prevention of atrial fibrillation after open heart surgery An economic analysis of amiodarone versus placebo for the prevention of atrial fibrillation after open heart surgery Reddy P, Dunn A B, White C M, Tsikouris J P, Giri S, Kluger J Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study evaluated prophylaxis with oral amiodarone in patients undergoing open heart surgery. The doses used are described in the 'Study Sample' field. Type of intervention Prophylaxis, (primary prevention). Economic study type Cost-effectiveness analysis. Study

2002 NHS Economic Evaluation Database.

45. Conversion of recent-onset atrial fibrillation with intravenous amiodarone: a meta-analysis of randomized controlled trials

Conversion of recent-onset atrial fibrillation with intravenous amiodarone: a meta-analysis of randomized controlled trials Conversion of recent-onset atrial fibrillation with intravenous amiodarone: a meta-analysis of randomized controlled trials Conversion of recent-onset atrial fibrillation with intravenous amiodarone: a meta-analysis of randomized controlled trials Hilleman D E, Spinler S A Authors' objectives To evaluate the efficacy and safety of intravenous amiodarone for conversion (...) of recent-onset atrial fibrillation (AF). Searching MEDLINE was searched from January 1975 to March 2001 for studies published in the English language. The search terms were 'atrial fibrillation', 'amiodarone' and 'cardioversion'. Pertinent review articles and the reference lists in the identified studies were examined for additional studies. Study selection Study designs of evaluations included in the review Randomised controlled trials (RCTs) were eligible. Specific interventions included

2002 DARE.

46. Amiodarone and rural emergency medical services cardiac arrest patients: a cost analysis

Amiodarone and rural emergency medical services cardiac arrest patients: a cost analysis Amiodarone and rural emergency medical services cardiac arrest patients: a cost analysis Amiodarone and rural emergency medical services cardiac arrest patients: a cost analysis Pazdral T E, Burton J H, Strout T D, Bradshaw J R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of amiodarone (150-mg vial) in a system-wide, rural prehospital treatment protocol for cardiac arrest patients was examined. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients identified by EMS personnel as presenting with a diagnosis of cardiac arrest. Patients

2002 NHS Economic Evaluation Database.

47. Effect of amiodarone +/- diltiazem +/- beta blocker on frequency of atrial fibrillation, length of hospitalization, and hospital costs after coronary artery bypass grafting

Effect of amiodarone +/- diltiazem +/- beta blocker on frequency of atrial fibrillation, length of hospitalization, and hospital costs after coronary artery bypass grafting Effect of amiodarone +/- diltiazem +/- beta blocker on frequency of atrial fibrillation, length of hospitalization, and hospital costs after coronary artery bypass grafting Effect of amiodarone +/- diltiazem +/- beta blocker on frequency of atrial fibrillation, length of hospitalization, and hospital costs after coronary (...) fibrillation (AF) in patients who had undergone coronary artery bypass grafting (CABG) was examined. The pathway was based on the administration of oral amiodarone, rate and rhythm control, cardioversion, and anticoagulation. Rate control, if needed, was mainly achieved with intravenous diltiazem and less often with a beta-blocker. Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients who had CABG

2002 NHS Economic Evaluation Database.

48. Amiodarone reduces procedures and costs related to atrial fibrillation in a controlled clinical trial

Amiodarone reduces procedures and costs related to atrial fibrillation in a controlled clinical trial Amiodarone reduces procedures and costs related to atrial fibrillation in a controlled clinical trial Amiodarone reduces procedures and costs related to atrial fibrillation in a controlled clinical trial Lumer G B, Roy D, Talajic M, Couturier A, Lambert J, Frasure-Smith N, Thibault B, Dubuc M, Gagne P, Nattel S Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Low-dose amiodarone was compared with other first-line therapy (sotalol or propafenone) for the treatment of atrial fibrillation (AF). Type of intervention Primary prevention. Economic study type Cost-effectiveness analysis. Study population The study population

2002 NHS Economic Evaluation Database.

49. Cost-effectiveness of targeting patients undergoing cardiac surgery for therapy with intravenous amiodarone to prevent atrial fibrillation

Cost-effectiveness of targeting patients undergoing cardiac surgery for therapy with intravenous amiodarone to prevent atrial fibrillation Cost-effectiveness of targeting patients undergoing cardiac surgery for therapy with intravenous amiodarone to prevent atrial fibrillation Cost-effectiveness of targeting patients undergoing cardiac surgery for therapy with intravenous amiodarone to prevent atrial fibrillation Mahoney E M, Thompson T D, Veledar E, Williams J, Weintraub W S Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of prophylactic intravenous (IV) amiodarone therapy for the prevention of atrial fibrillation (AF) in patients undergoing cardiac surgery. Type of intervention Secondary prevention. Economic study type

2002 NHS Economic Evaluation Database.

50. Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation

Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2002 PedsCCM Evidence-Based Journal Club

51. Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction. (Abstract)

Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction. Clinical trials have shown that implantable cardioverter defibrillators (ICDs) improve survival in patients with sustained ventricular arrhythmias.To determine the efficacy necessary to make prophylactic ICD or amiodarone therapy cost-effective in patients with myocardial infarction.Markov model-based cost utility analysis.Survival, cardiac death (...) , and inpatient costs were estimated on the basis of the Myocardial Infarction Triage and Intervention registry. Other data were derived from the literature.Patients with past myocardial infarction who did not have sustained ventricular arrhythmia.Lifetime.Societal.ICD or amiodarone compared with no treatment.Life-years, quality-adjusted life-years (QALYs), costs, number needed to treat, and incremental cost-effectiveness.Compared with no treatment, ICD use led to the greatest QALYs and the highest

2001 Annals of Internal Medicine

52. Oral amiodarone for prevention of atrial fibrillation after open heart surgery, the Atrial Fibrillation Suppression Trial (AFIST): a randomised placebo-controlled trial. (Abstract)

Oral amiodarone for prevention of atrial fibrillation after open heart surgery, the Atrial Fibrillation Suppression Trial (AFIST): a randomised placebo-controlled trial. Beta-blockers and amiodarone reduce the frequency of atrial fibrillation after open-heart surgery but the effectiveness of oral amiodarone in older patients already receiving beta-blockers is unknown. We have assessed the efficacy of oral amiodarone in preventing atrial fibrillation in patients aged 60 years or older undergoing (...) open-heart surgery.We did a randomised, double-blind placebo-controlled trial in which patients undergoing open-heart surgery (n=220, average age 73 years) received amiodarone (n=120) or placebo (n=100). Patients enrolled less than 5 days before surgery received 6 g of amiodarone or placebo over 6 days beginning on preoperative day 1. Patients enrolled at least 5 days before surgery received 7 g over 10 days beginning on preoperative day 5.Patients on amiodarone had a lower frequency of any atrial

2001 Lancet Controlled trial quality: predicted high

53. Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction

Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction Sanders G D, Hlatky M A, Every N R, McDonald K M, Heidenreich P A, Parsons L S, Owens D (...) K Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Two prophylactic strategies for patients who had myocardial infarction (MI) were examined. The strategies were implantable cardioverter defibrillator (ICD) and amiodarone (AMIO

2001 NHS Economic Evaluation Database.

54. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. (Abstract)

Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. The restoration and maintenance of sinus rhythm is a desirable goal in patients with atrial fibrillation, because the prevention of recurrences can improve cardiac function and relieve symptoms. Uncontrolled studies have suggested that amiodarone in low doses may be more effective and safer than other agents in preventing recurrence, but this agent has not been tested in a large (...) , randomized trial.We undertook a prospective, multicenter trial to test the hypothesis that low doses of amiodarone would be more efficacious in preventing recurrent atrial fibrillation than therapy with sotalol or propafenone. We randomly assigned patients who had had at least one episode of atrial fibrillation within the previous six months to amiodarone or to sotalol or propafenone, given in an open-label fashion. The patients in the group assigned to sotalol or propafenone underwent a second

2000 NEJM Controlled trial quality: uncertain

55. Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. (Abstract)

Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. Whether antiarrhythmic drugs improve the rate of successful resuscitation after out-of-hospital cardiac arrest has not been determined in randomized clinical trials.We conducted a randomized, double-blind, placebo-controlled study of intravenous amiodarone in patients with out-of-hospital cardiac arrest. Patients who had cardiac arrest with ventricular fibrillation (or pulseless ventricular (...) tachycardia) and who had not been resuscitated after receiving three or more precordial shocks were randomly assigned to receive 300 mg of intravenous amiodarone (246 patients) or placebo (258 patients).The treatment groups had similar clinical profiles. There was no significant difference between the amiodarone and placebo groups in the duration of the resuscitation attempt (42+/-16.4 and 43+/-16.3 minutes, respectively), the number of shocks delivered (4+/-3 and 6+/-5), or the proportion of patients who

1999 NEJM Controlled trial quality: predicted high

56. Cost-effectiveness of amiodarone for prophylaxis of atrial fibrillation in coronary artery bypass surgery

Cost-effectiveness of amiodarone for prophylaxis of atrial fibrillation in coronary artery bypass surgery Cost-effectiveness of amiodarone for prophylaxis of atrial fibrillation in coronary artery bypass surgery Cost-effectiveness of amiodarone for prophylaxis of atrial fibrillation in coronary artery bypass surgery Reddy P, Richerson M, Freeman-Bosco L, Dunn A, White C M, Chow M S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS (...) EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Amiodarone for prophylaxis of atrial fibrillation in coronary artery bypass surgery. Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients undergoing CABG. Setting The setting was hospital

1999 NHS Economic Evaluation Database.

57. Overview and meta-analysis of randomised trials of amiodarone in chronic heart failure

Overview and meta-analysis of randomised trials of amiodarone in chronic heart failure Overview and meta-analysis of randomised trials of amiodarone in chronic heart failure Overview and meta-analysis of randomised trials of amiodarone in chronic heart failure Piepoli M, Villani G Q, Ponikowski P, Wright A, Flather M D, Coats A J Authors' objectives To evaluate the role of amiodarone in chronic heart failure. Searching Literature was scanned using a 'formal, computer-aided search'. No further (...) details were given. Study selection Study designs of evaluations included in the review Randomised controlled trials (RCTs) of amiodarone with objective and reproducible entry criteria were included. Follow-up periods ranged from 6 months to 6 years. Specific interventions included in the review Amiodarone in doses ranging from 8 mg/day to 1000mg/day was compared with conventional arrythmic therapy, no therapy and placebo. Participants included in the review Patients with the following medical

1998 DARE.

58. Cost-effectiveness analysis of invasive and noninvasive tests in high risk patients treated with amiodarone after acute myocardial infarction

Cost-effectiveness analysis of invasive and noninvasive tests in high risk patients treated with amiodarone after acute myocardial infarction Cost-effectiveness analysis of invasive and noninvasive tests in high risk patients treated with amiodarone after acute myocardial infarction Cost-effectiveness analysis of invasive and noninvasive tests in high risk patients treated with amiodarone after acute myocardial infarction Pedretti R F, Migliori G B, Mapelli V, Daniele G, Podrid P J, Tramarin R (...) Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Invasive and non-invasive diagnostic tests and amiodarone treatment after acute myocardial infarction. Type of intervention Diagnosis; treatment. Economic study type Cost-utility

1998 NHS Economic Evaluation Database.

59. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. (Abstract)

Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Ventricular arrhythmias are a major cause of death after myocardial infarction, especially in patients with poor left-ventricular function. Previous attempts to identify and suppress arrhythmias with various antiarrhythmic drugs failed to reduce or actually increase mortality. Amiodarone (...) is a powerful antiarrhythmic drug with several potentially beneficial actions, and has shown benefit in several small-scale studies. We postulated that this drug might reduce mortality in patients at high risk of death after myocardial infarction because of impaired ventricular function, irrespective of whether they had ventricular arrhythmias.The European Myocardial Infarct Amiodarone Trial (EMIAT) was a randomised double-blind placebo-controlled trial to assess whether amiodarone reduced all-cause

1997 Lancet Controlled trial quality: predicted high

60. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. (Abstract)

Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Survivors of acute myocardial infarction with frequent or repetitive ventricular premature depolarisations (VPDs) have higher mortality 1-2 years after the event than those without VPDs. Although there is no therapy of proven efficacy for such patients, previous studies (...) of amiodarone have been encouraging. CAMIAT was a randomised double-blind placebo-controlled trial designed to assess the effect of amiodarone on the risk of resuscitated ventricular fibrillation or arrhythmic death among survivors of myocardial infarction with frequent or repetitive VPDs (> or = 10 VPDs per h or > or = 1 run of ventricular tachycardia).Patients from 36 Canadian hospitals were randomly assigned amiodarone or placebo; a loading dose of 10 mg/kg daily for 2 weeks, a maintenance dose of 300

1997 Lancet Controlled trial quality: predicted high